Alexion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALXN)

$121.05 0.70 (0.58 %)
(As of 01/21/2018 01:15 PM ET)
Previous Close$121.05
Today's Range$120.38 - $121.73
52-Week Range$96.18 - $149.34
Volume1.75 million shs
Average Volume2.10 million shs
Market Capitalization$27.04 billion
P/E Ratio54.04
Dividend YieldN/A
Beta1.17

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ALXN
CUSIP01535110
Phone+1-203-2722596

Debt

Debt-to-Equity Ratio0.35%
Current Ratio2.96%
Quick Ratio2.51%

Price-To-Earnings

Trailing P/E Ratio54.0401785714286
Forward P/E Ratio25.11
P/E Growth1.01

Sales & Book Value

Annual Sales$3.08 billion
Price / Sales8.77
Cash Flow$6.00 per share
Price / Cash20.16
Book Value$38.82 per share
Price / Book3.12

Profitability

Trailing EPS$2.24
Net Income$399 million
Net Margins14.57%
Return on Equity12.55%
Return on Assets8.25%

Miscellaneous

Employees3,121
Outstanding Shares223,410,000

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals declared that its board has initiated a stock buyback plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.32 by $0.12. The biopharmaceutical company earned $859 million during the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When will Alexion Pharmaceuticals make its next earnings announcement?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY17 earnings guidance on Thursday, October, 26th. The company provided EPS guidance of $5.50-5.65 for the period, compared to the Thomson Reuters consensus estimate of $5.60. The company issued revenue guidance of $3.475-3.525 billion, compared to the consensus revenue estimate of $3.53 billion.

Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2018?

20 brokers have issued 12-month price targets for Alexion Pharmaceuticals' stock. Their predictions range from $120.00 to $180.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $154.16 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.

What are Wall Street analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alexion topped earnings estimates but missed on revenues in the third quarter. The increase in earnings guidance was also positive. Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis will further boost sales. Among new products, while Strensiq is gaining momentum, the company redefined its strategy for Kanuma which earlier lagged expectations. In order to focus better in core areas, Alexion has de-prioritized a few clinical programs and terminated its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. However, the company relies heavily on Soliris for growth and sales of Soliris will be impacted by ramp of ALXN1210 trials while pricing will impact Strensiq revenues going forward.Shares of the company have underperformed the industry in the last six months." (11/1/2017)
  • 2. JPMorgan Chase & Co. analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)
  • 3. Morgan Stanley analysts commented, "re-prioritize the strategic direction" of the company. Furthermore, the second-quarter strategic review serves as a "turning point" for investor sentiment."While we understand investor unease that another 'shoe could drop' on this story, we see the risk/reward as compelling and believe new management is making progress right sizing the company and refocusing its efforts," the analyst wrote.2. Underappreciated StoryHarrison also believes Alexion's stock is pricing "little-to-no value" for the ALXN1210 life-cycle extension strategy. Meanwhile, investors are under-appreciating the antibody but the sentiment could turn move positive with potential gMG approval and the release of pivotal data.Harrison also believes Alexion's core asset value is "not impaired." Also, the analyst suggested that the underlying patient need and use of Solaris is "sound" and the company's strategy to protect Solaris through new IP and ALXN1210 is "very defensible with clarity on this strategy coming in less than 12 months." (5/25/2017)
  • 4. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:

  • David R. Brennan, Chairman of the Board (Age 63)
  • Ludwig N. Hantson Ph.D., Chief Executive Officer, Director (Age 54)
  • Paul J. Clancy, Chief Financial Officer (Age 55)
  • John B. Moriarty J.D., Executive Vice President, General Counsel (Age 49)
  • Julie O'Neill, Executive Vice President - Global Operations (Age 50)
  • Edward Miller J.D., Senior Vice President, Global Chief Compliance Officer (Age 52)
  • Heidi L. Wagner J.D., Senior Vice President - Global Governmental Affairs (Age 52)
  • Brian Goff, Chief Commercial Officer (Age 48)
  • Paul A. Friedman M.D., Director (Age 74)
  • Francois E. Nader M.D., Director (Age 60)

Who owns Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.68%), Schwab Charles Investment Management Inc. (0.41%), Factory Mutual Insurance Co. (0.16%), National Pension Service (0.09%), Gateway Investment Advisers LLC (0.06%) and Exxonmobil Investment Management Inc. TX (0.02%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Martin Mackay and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Who sold Alexion Pharmaceuticals stock? Who is selling Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Lockheed Martin Investment Management Co., Exxonmobil Investment Management Inc. TX, Westpac Banking Corp, Tealwood Asset Management Inc., Livforsakringsbolaget Skandia Omsesidigt, Covenant Asset Management LLC and Edge Wealth Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Carsten Thiel, Clare Carmichael, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Who bought Alexion Pharmaceuticals stock? Who is buying Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Factory Mutual Insurance Co., Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Creative Planning, Ingalls & Snyder LLC, National Pension Service and Moody National Bank Trust Division. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy Alexion Pharmaceuticals stock?

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $121.05.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $27.04 billion and generates $3.08 billion in revenue each year. The biopharmaceutical company earns $399 million in net income (profit) each year or $2.24 on an earnings per share basis. Alexion Pharmaceuticals employs 3,121 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 College St, NEW HAVEN, CT 06510-3210, United States. The biopharmaceutical company can be reached via phone at +1-203-2722596.


MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  852 (Vote Outperform)
Underperform Votes:  454 (Vote Underperform)
Total Votes:  1,306
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alexion Pharmaceuticals (NASDAQ:ALXN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.952.822.78
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $154.16$157.58$155.14$157.86
Price Target Upside: 26.23% upside36.13% upside11.60% upside24.58% upside

Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History

Price Target History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$147.00MediumView Rating Details
1/4/2018Raymond James FinancialReiterated RatingStrong-Buy -> Outperform$178.00 -> $130.00MediumView Rating Details
12/18/2017Robert W. BairdUpgradeNeutral -> Outperform$150.00MediumView Rating Details
12/6/2017Leerink SwannReiterated RatingBuy$169.00LowView Rating Details
10/24/2017Royal Bank of CanadaBoost Price Target$166.00N/AView Rating Details
10/24/2017Stifel NicolausLower Price TargetBuy$165.00 -> $159.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$170.00N/AView Rating Details
9/13/2017Deutsche BankReiterated RatingBuy -> Buy$153.00 -> $158.00LowView Rating Details
9/13/2017SunTrust BanksReiterated RatingBuy$170.00 -> $180.00MediumView Rating Details
9/13/2017BMO Capital MarketsReiterated RatingOutperform$168.00 -> $173.00MediumView Rating Details
9/5/2017JPMorgan Chase & Co.UpgradeNeutral -> Overweight$163.00 -> $175.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$137.00MediumView Rating Details
7/28/2017OppenheimerUpgradeMarket Perform -> Outperform$175.00HighView Rating Details
7/28/2017Morgan StanleyReiterated RatingOverweight$141.00 -> $153.00HighView Rating Details
7/3/2017CowenReiterated RatingOutperform$122.00HighView Rating Details
6/9/2017Goldman Sachs GroupReiterated RatingBuy$142.00LowView Rating Details
6/8/2017Jefferies GroupSet Price TargetHold$120.00MediumView Rating Details
5/24/2017BarclaysReiterated RatingOverweight$155.00HighView Rating Details
3/30/2017InstinetReiterated RatingBuy$148.00LowView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00N/AView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/AView Rating Details
9/20/2016CitigroupBoost Price TargetBuy$154.00 -> $155.00N/AView Rating Details
6/6/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings History and Estimates Chart

Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ ALXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018$1.27N/AView Earnings Details
10/26/2017Q3 2017$1.32$1.44$864.34 million$859.00 millionViewN/AView Earnings Details
7/27/2017Q2 2017$1.08$1.56$846.15 million$912.00 millionViewN/AView Earnings Details
4/27/2017Q1 2017$1.05$1.38$826.63 million$870.00 millionViewN/AView Earnings Details
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$0.91$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.31$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.18$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.17$1.13$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.05$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$0.99$0.99$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
10/21/2010Q3 2010$0.19$0.15ViewN/AView Earnings Details
7/22/2010Q2 2010$0.15$0.16ViewN/AView Earnings Details
4/22/2010Q1 2010$0.12$0.11ViewN/AView Earnings Details
2/11/2010Q4 2009$0.12$0.12ViewN/AView Earnings Details
10/22/2009Q3 2009$0.11$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009$0.09$0.11ViewN/AView Earnings Details
4/23/2009Q1 2009$0.07$0.08ViewN/AView Earnings Details
2/12/2009Q4 2008$0.05$0.08ViewN/AView Earnings Details
10/23/2008Q3 2008$0.02$0.11ViewN/AView Earnings Details
7/29/2008Q2 2008($0.04)$0.02ViewN/AView Earnings Details
4/30/2008Q1 2008($0.11)($0.03)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.12)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings Estimates

Current Year EPS Consensus Estimate: $4.82 EPS
Next Year EPS Consensus Estimate: $6.25 EPS

Dividends

Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 94.27%
Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Ludwig HantsonCEOSell2,553$121.63$310,521.3936,172View SEC Filing  
10/2/2017Heidi L WagnerSVPSell120$140.00$16,800.00View SEC Filing  
9/5/2017Ann M VenemanDirectorSell835$145.81$121,751.355,480View SEC Filing  
9/5/2017Julie O'neillEVPSell4,375$145.44$636,300.0026,092View SEC Filing  
8/28/2017Julie O'neillEVPSell11,160$140.00$1,562,400.0026,704View SEC Filing  
7/31/2017Ann M VenemanDirectorSell700$137.74$96,418.006,315View SEC Filing  
6/15/2017Bros. Advisors Lp BakerDirectorBuy660,779$117.33$77,529,200.07View SEC Filing  
6/14/2017Bros. Advisors Lp BakerDirectorBuy1,348,955$116.32$156,910,445.60View SEC Filing  
6/14/2017Ludwig HantsonCEOBuy10,000$116.72$1,167,200.0038,725View SEC Filing  
3/1/2017Clare CarmichaelEVPSell2,179$131.66$286,887.1433,980View SEC Filing  
3/1/2017Heidi L WagnerSVPSell994$131.65$130,860.1029,646View SEC Filing  
3/1/2017Leonard BellDirectorSell3,978$131.96$524,936.88391,910View SEC Filing  
2/28/2017Carsten ThielEVPSell125$74.52$9,315.0030,197View SEC Filing  
2/28/2017Edward MillerSVPSell590$131.48$77,573.2015,214View SEC Filing  
2/28/2017Leonard BellDirectorSell2,738$131.71$360,621.98391,910View SEC Filing  
2/27/2017Edward MillerSVPSell260$131.20$34,112.0015,214View SEC Filing  
2/27/2017John B MoriartyEVPSell612$131.20$80,294.4045,864View SEC Filing  
2/9/2017John B MoriartyEVPSell167$126.84$21,182.2846,476View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64394,648View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.0430,241View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.0246,801View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25395,979View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00403,719View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20438,497View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.6514,305View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.8450,181View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.0030,433View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.9031,936View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46440,936View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00406,589View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.5232,741View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.8937,325View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.2031,995View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.7540,354View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.4416,519View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.0040,579View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.5035,384View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.0038,577View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.006,373View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.006,373View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.1039,577View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48189,266View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.0832,115View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40405,289View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78178,463View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.9651,360View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.4042,706View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.4532,337View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32189,632View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.9241,054View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02193,026View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.3917,215View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40742,222View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02179,862View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50173,026View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.4429,937View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.1430,348View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76746,192View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88171,862View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.0214,215View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00749,259View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00749,259View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.603,252View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.3941,340View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00849,088View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.0036,385View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00919,088View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.5238,310View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00919,088View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.001,032,331View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.9024,426View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.284,840View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.001,032,331View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20101,308View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40113,965View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.8619,670View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00179,217View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20986,696View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00963,276View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.6894,818View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44129,775View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60975,066View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58103,068View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80977,726View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.901,031,957View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.001,031,957View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00179,217View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.001,026,293View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.501,003,519View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.469,463View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.001,036,669View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.531,176,669View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alexion Pharmaceuticals (NASDAQ ALXN) News Headlines

Source:
DateHeadline
Cardiome Pharma (CRME) versus Alexion Pharmaceuticals (ALXN) Critical ContrastCardiome Pharma (CRME) versus Alexion Pharmaceuticals (ALXN) Critical Contrast
www.americanbankingnews.com - January 21 at 3:24 AM
FY2017 Earnings Forecast for Alexion Pharmaceuticals, Inc. Issued By Leerink Swann (ALXN)FY2017 Earnings Forecast for Alexion Pharmaceuticals, Inc. Issued By Leerink Swann (ALXN)
www.americanbankingnews.com - January 19 at 8:16 AM
The Key To Alexions Long-Term Upside Potential, According To Credit SuisseThe Key To Alexion's Long-Term Upside Potential, According To Credit Suisse
finance.yahoo.com - January 19 at 6:34 AM
Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018
finance.yahoo.com - January 18 at 3:17 PM
Credit Suisse Group Reaffirms "Buy" Rating for Alexion Pharmaceuticals (ALXN)Credit Suisse Group Reaffirms "Buy" Rating for Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - January 18 at 8:28 AM
Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $876.57 MillionAlexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $876.57 Million
www.americanbankingnews.com - January 16 at 10:52 PM
 Analysts Expect Alexion Pharmaceuticals, Inc. (ALXN) Will Post Earnings of $1.28 Per Share Analysts Expect Alexion Pharmaceuticals, Inc. (ALXN) Will Post Earnings of $1.28 Per Share
www.americanbankingnews.com - January 14 at 1:08 AM
ALXN March 2nd Options Begin TradingALXN March 2nd Options Begin Trading
www.nasdaq.com - January 11 at 3:16 PM
A Look at Ionis Pharmaceuticals’ January 2018 ValuationA Look at Ionis Pharmaceuticals’ January 2018 Valuation
finance.yahoo.com - January 10 at 3:16 PM
Alexion Pharmaceuticals, Inc. (ALXN) Receives Average Rating of "Buy" from BrokeragesAlexion Pharmaceuticals, Inc. (ALXN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 10 at 1:44 AM
Implied FBT Analyst Target Price: $151 - NasdaqImplied FBT Analyst Target Price: $151 - Nasdaq
www.nasdaq.com - January 8 at 11:19 AM
Alexion Pharmaceuticals (ALXN) "Outperform" Rating Reiterated at Raymond James FinancialAlexion Pharmaceuticals' (ALXN) "Outperform" Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - January 8 at 12:44 AM
JPMorgan Healthcare Conference next week - Seeking AlphaJPMorgan Healthcare Conference next week - Seeking Alpha
seekingalpha.com - January 5 at 5:25 AM
Insider Selling: Alexion Pharmaceuticals, Inc. (ALXN) CEO Sells 2,553 Shares of StockInsider Selling: Alexion Pharmaceuticals, Inc. (ALXN) CEO Sells 2,553 Shares of Stock
www.americanbankingnews.com - January 4 at 9:28 PM
Sorry Alexion! Biotech Rally Will Leave You BehindSorry Alexion! Biotech Rally Will Leave You Behind
finance.yahoo.com - January 4 at 3:16 PM
UBS Group Lowers Alexion Pharmaceuticals (ALXN) to OutperformUBS Group Lowers Alexion Pharmaceuticals (ALXN) to Outperform
www.americanbankingnews.com - January 4 at 7:44 AM
Alexion to work with activist investor Elliott to fill board seatAlexion to work with activist investor Elliott to fill board seat
www.marketwatch.com - January 3 at 3:16 PM
Alexion Pharma (ALXN), Elliott Agree to Collaborate on Identifying New Board MemberAlexion Pharma (ALXN), Elliott Agree to Collaborate on Identifying New Board Member
www.streetinsider.com - January 3 at 3:16 PM
Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat - Wall Street JournalAlexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat - Wall Street Journal
www.wsj.com - January 3 at 11:19 AM
Alexion, Elliott to collaborate on new Alexion board memb...Alexion, Elliott to collaborate on new Alexion board memb...
finance.yahoo.com - January 2 at 8:17 PM
Alexion, Elliott to jointly look for new directorAlexion, Elliott to jointly look for new director
finance.yahoo.com - January 2 at 8:17 PM
[$$] Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat[$$] Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat
finance.yahoo.com - January 2 at 8:17 PM
Alexion to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAlexion to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 3:16 PM
Why These 2 Biotechs Could Outperform Amid 'Hyper-Competition'Why These 2 Biotechs Could Outperform Amid 'Hyper-Competition'
finance.yahoo.com - January 2 at 3:16 PM
Analyst names Vertex and Alexion top picks for 2018Analyst names Vertex and Alexion 'top picks for 2018'
finance.yahoo.com - January 2 at 3:16 PM
Piper Jaffray analyst: What to expect from biotech in 201...Piper Jaffray analyst: What to expect from biotech in 201...
finance.yahoo.com - January 2 at 3:16 PM
$876.57 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter$876.57 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter
www.americanbankingnews.com - December 30 at 1:50 PM
[$$] Dow Industrials End Solid 2017 on a Sour Note[$$] Dow Industrials End Solid 2017 on a Sour Note
finance.yahoo.com - December 30 at 5:52 AM
Alexion Pharmaceuticals (ALXN) Upgraded to Sell at BidaskClubAlexion Pharmaceuticals (ALXN) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - December 28 at 8:42 PM
Major Biotechs See Surge in Short InterestMajor Biotechs See Surge in Short Interest
247wallst.com - December 28 at 3:00 PM
$1.28 Earnings Per Share Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter$1.28 Earnings Per Share Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter
www.americanbankingnews.com - December 28 at 10:24 AM
Zacks: Analysts Anticipate Alexion Pharmaceuticals, Inc. (ALXN) to Announce $1.28 EPSZacks: Analysts Anticipate Alexion Pharmaceuticals, Inc. (ALXN) to Announce $1.28 EPS
www.americanbankingnews.com - December 28 at 10:20 AM
Wired News - Alexion Announced Marketing Authorization of Soliris® in Japan for Treatment of Patients with Generalized Myasthenia GravisWired News - Alexion Announced Marketing Authorization of Soliris® in Japan for Treatment of Patients with Generalized Myasthenia Gravis
finance.yahoo.com - December 28 at 8:01 AM
Alexions (ALXN) Soliris Label Expansion Approved in Japan - Nasdaq - NasdaqAlexion's (ALXN) Soliris Label Expansion Approved in Japan - Nasdaq - Nasdaq
www.nasdaq.com - December 27 at 7:28 PM
Alexions (ALXN) Soliris Label Expansion Approved in JapanAlexion's (ALXN) Soliris Label Expansion Approved in Japan
finance.yahoo.com - December 27 at 2:27 PM
Alexion Pharma (ALXN) Soliris Granted Marketing Authorization in JapanAlexion Pharma (ALXN) Soliris Granted Marketing Authorization in Japan
www.streetinsider.com - December 26 at 7:22 PM
Alexion Pharma (ALXN) Soliris Granted Marketing Authorization in Japan - StreetInsider.comAlexion Pharma (ALXN) Soliris Granted Marketing Authorization in Japan - StreetInsider.com
www.streetinsider.com - December 26 at 1:38 PM
Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
finance.yahoo.com - December 26 at 1:38 PM
Alexion Pharmaceuticals (ALXN) Stock Rating Reaffirmed by Credit Suisse GroupAlexion Pharmaceuticals (ALXN) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - December 25 at 8:50 AM
Oppenheimer Stays Bullish On Alexion Pharma - BenzingaOppenheimer Stays Bullish On Alexion Pharma - Benzinga
www.benzinga.com - December 21 at 5:32 AM
First Week of August 2018 Options Trading For Alexion Pharmaceuticals (ALXN) - NasdaqFirst Week of August 2018 Options Trading For Alexion Pharmaceuticals (ALXN) - Nasdaq
www.nasdaq.com - December 21 at 5:32 AM
Oppenheimer Stays Bullish On Alexion PharmaOppenheimer Stays Bullish On Alexion Pharma
finance.yahoo.com - December 21 at 5:32 AM
Alexion to Present at the Goldman Sachs Healthcare CEOs Unscripted ConferenceAlexion to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
finance.yahoo.com - December 20 at 3:15 PM
Oppenheimer Serves Up 29 Top Stock Ideas For January - BenzingaOppenheimer Serves Up 29 Top Stock Ideas For January - Benzinga
www.benzinga.com - December 20 at 5:23 AM
7 Best Bets in Biotech: From Alexion to Regeneron7 Best Bets in Biotech: From Alexion to Regeneron
finance.yahoo.com - December 19 at 3:15 PM
Alexion Pharmaceuticals (ALXN) Raised to Outperform at Robert W. BairdAlexion Pharmaceuticals (ALXN) Raised to Outperform at Robert W. Baird
www.americanbankingnews.com - December 18 at 9:54 PM
Baird Upgrades Alexion Pharmaceuticals (ALXN) to Outperform ... - StreetInsider.comBaird Upgrades Alexion Pharmaceuticals (ALXN) to Outperform ... - StreetInsider.com
www.streetinsider.com - December 18 at 3:15 PM
Alexion Pharmaceuticals, Inc. (ALXN) Given Consensus Rating of "Buy" by AnalystsAlexion Pharmaceuticals, Inc. (ALXN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 16 at 1:52 AM
Alexion Pharma (ALXN) Announces Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with PNH Presented at ASHAlexion Pharma (ALXN) Announces Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with PNH Presented at ASH
www.streetinsider.com - December 12 at 3:15 PM
ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 3:15 PM

SEC Filings

Alexion Pharmaceuticals (NASDAQ:ALXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alexion Pharmaceuticals (NASDAQ:ALXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alexion Pharmaceuticals (NASDAQ ALXN) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.